Boardroom Alpha
Start trial
10-K primary document
ABBV · Annual Report (Form 10-K) · Filed February 20, 2026

Abbvie Inc — 10-K exhibit

abbv-20251231xex23.htm
Abbvie Inc on Boardroom Alpha
Document
Exhibit 23
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1)Registration Statements (Form S-8 No. 333-185561, Form S-3 No. 333-207422, and Form S-8 No. 333-222107) pertaining to the AbbVie 2013 Incentive Stock Program,
(2)Registration Statement (Form S-8 No. 333-185562) pertaining to the AbbVie 2013 Employee Stock Purchase Plan for Non-U.S. Employees,
(3)Registration Statements (Form S-8 No. 333-185563 and Form S-8 No. 333-222105) pertaining to the AbbVie Deferred Compensation Plan,
(4)Registration Statement (Form S-8 No. 333-185564 and Form S-8 No. 333-282982) pertaining to the AbbVie Savings Program,
(5)Registration Statement (Form S-8 No. 333-204466) pertaining to the Pharmacyclics, Inc. 2014 Equity Incentive Award Plan,
(6)Registration Statement (Form S-8 No. 333-212067) pertaining to the Stemcentrx 2011 Equity Incentive Plan,
(7)Registration Statement (Form S-3 No. 333-238302) pertaining to common stock of AbbVie Inc.,
(8)Registration Statement (Form S-8 No. 333-256045) pertaining to the AbbVie Amended and Restated 2013 Incentive Stock Program,
(9)Registration Statement (Form S-8 No. 333-268192 and Form S-8 No. 333-282981) pertaining to the AbbVie Deferred Compensation Plan and the AbbVie Deferred Compensation Plan Plus,
(10)Registration Statement (Form S-8 No. 333-277293) pertaining to the ImmunoGen, Inc. Amended and Restated 2018 Employee, Director and Consultant Equity Incentive Plan and the ImmunoGen, Inc. Inducement Equity Incentive Plan, As Amended,
(11)Registration Statement (Form S-8 No. 333-281545) pertaining to the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan,
(12)Registration Statement (Form S-3 No. 333-262908) pertaining to debt securities of AbbVie Inc., and
(13)Registration Statement (Form S-3 No. 333-284980) pertaining to debt securities of AbbVie Inc.;
of our reports dated February 20, 2026, with respect to the consolidated financial statements of AbbVie Inc. and subsidiaries and the effectiveness of internal control over financial reporting of AbbVie Inc. and subsidiaries included in this Annual Report (Form 10-K) of AbbVie Inc. and subsidiaries for the year ended December 31, 2025.
/s/ Ernst & Young LLP
Chicago, Illinois
February 20, 2026

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer